Anti-obesity drug development
- 1 September 2002
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 11 (9) , 1189-1204
- https://doi.org/10.1517/13543784.11.9.1189
Abstract
Obesity accelerates morbidity and mortality and has been described by the World Health Organization (WHO) as an epidemic in many industrialised nations [101,102]. Diet, exercise and lifestyle recommendations have proven to be mostly ineffective in adequately preventing or treating the progression of this public health disease. Existing drug treatment is limited by the scarce number of safe and well-tolerated drugs with proven long-term efficacy in maintaining weight loss. Numerous anti-obesity drugs in development have promise. Yet, despite that obesity is the single most common nutritional problem in many developed nations and despite the devastating health consequences of this unchecked epidemic, investigational anti-obesity drugs face unique and significant challenges due to past and current experiences with anti-obesity drugs. It is anticipated that new anti-obesity drugs for this serious, multifaceted metabolic disease will become as safe and effective and as medically accepted as the treatment of ot...Keywords
This publication has 55 references indexed in Scilit:
- Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)Published by Elsevier ,2004
- The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjectsInternational Journal of Obesity, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- PPAR.GAMMA. agonist and antagonist.Folia Pharmacologica Japonica, 2001
- Novel anti-obesity drugsExpert Opinion on Investigational Drugs, 2000
- The role of NPY in metabolic homeostasis: implications for obesity therapyExpert Opinion on Investigational Drugs, 2000
- Dose-effect of fenfluramine use on the severity of valvular heart disease among fen-phen patients with valvulopathyInternational Journal of Obesity, 1999
- Thermogenic effects of sibutramine and its metabolitesBritish Journal of Pharmacology, 1999
- Unusual Hypotension and Bradycardia in a Patient Receiving Fenfluramine, Phentermine, and FluoxetimeAnesthesiology, 1998
- Association of β3-adrenoceptor polymorphism with obesity and diabetes: current statusTrends in Pharmacological Sciences, 1997